Fabry Disease, Uncategorized

Amicus Therapeutics Is Moving Into The 21st Century With Purpose and Determination

Amicus Therapeutics is a biopharmaceutical company located in New Jersey that focuses on rare and orphan diseases. With a spread of treatments in late developmental stages for a variety of human genetic diseases, Amicus Therapeutics looks to continue to move into the 21st century with the goal of helping as many people as possible. Their main product being featured is called migalastat, which is a medicine that can help treat people who suffer from Fabry disease. Migalastat is in the late stages of its development and works with individuals based on the diagnosis of their genes. Another possible medicine that is in the later stages of its development is SD-101, which aims to help people who have a rare genetic disorder named Epidermolysis Bullosa (EB) (GoogleFinance).

 

Amicus Therapeutics also advocates for its patients and others by teaming up with individual patients, patient organizations, caregivers, and healthcare professionals. Their consistent efforts to offer up initiatives that help people with rare diseases to find support, purpose, and resources have aided in the continuing fight for the rights of these people to get the help they need. By continuing to beat these people’s sides far after their medical treatment, Amicus Therapeutics is bringing hope to a whole new generation and especially people who suffer from CDKL5 deficiency, Epidermolysis Bullosa, and Lysosomal Storage Disorder. Much of what Amicus Therapeutics does in this vein is to listen and learn from people that suffer from these diseases, aim to find better cures or therapies that will work, and offer resources and information to those who are suffering from these diseases.

 

John F. Crowley has been the CEO at Amicus Therapeutics since 2005, and he also became Chairman of The Board in 2010. He is happy that he is part of a company that continues to prove its resilience and dedication to its goals. He looks forward to showing up every single day and energizing his team with the vision of the company to achieve its goals through science, a strong team of people who believe in the cause, and keeping their goals aligned with the original purpose of the company, which is to always put the people they serve first.

More at https://www.glassdoor.com/Reviews/Amicus-Therapeutics-Reviews-E26068.htm

Tags :
September 19, 2017